Pyxis Oncology Files 8-K on Financials

Ticker: PYXS · Form: 8-K · Filed: 2024-03-21T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, operations, filing

TL;DR

Pyxis Oncology dropped an 8-K detailing its financials and operations.

AI Summary

Pyxis Oncology, Inc. filed an 8-K on March 21, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 321 Harrison Avenue, Boston, MA.

Why It Matters

This 8-K filing provides crucial updates on Pyxis Oncology's financial health and operational status, which is essential for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant news that impacts stock price, requiring careful review by investors.

Key Numbers

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

This 8-K filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific dollar amounts or detailed financial statements within the provided text.

What is the primary purpose of this 8-K filing for Pyxis Oncology?

The primary purpose is to report on the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits.

When was this 8-K filing submitted?

The filing was submitted on March 21, 2024.

Where are Pyxis Oncology's principal executive offices located?

Pyxis Oncology's principal executive offices are located at 321 Harrison Avenue, Boston, Massachusetts.

What is the Commission File Number for Pyxis Oncology?

The Commission File Number for Pyxis Oncology is 001-40881.

Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-21 07:44:08

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On March 21, 2024, Pyxis Oncology, Inc. ("the Company") issued a press release announcing its financial results for the full year ended December 31, 2023 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On March 21, 2024, the Company made available an updated corporate presentation on the Company's website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in Items 2.02 and 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 21, 2024 99.2 Pyxis Oncology Corporate Presentation dated March 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Pyxis Oncology, Inc. Date: March 21, 2024 By: /s/ Pamela Connealy Pamela Connealy Chief Financial Officer and Chief Operating Officer

View on Read The Filing